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Abstract
Background: The emergence of nanomedicine in the past decade has changed the landscape of disease diagnosis
and treatment. Nanomedicine makes use of nanostructures for applications in different fields of medicine, including
drug delivery, biosensors, neuro-electronic interfaces, in vivo imaging, and cell-specific molecular interactions. Despite
its relative infancy, nanomedicine has generated a significant body of research as evidenced by peer reviewed
literature and several patents. This proposed systematic review will focus specifically on drug delivery systems in
which nanoparticles are used to enhance the pharmacological and therapeutic properties of drugs. The strength
of nanoparticulate drug delivery systems is their ability to alter the pharmacokinetics and bio-distribution of drugs.
Globally, the discourse on nanomedicine is dominated by research being done in the developed countries of Europe
and in the United States of America. Less attention has been given to the applications of nanomedicine in developing
countries, particularly Africa. There is dearth of information on the applications of nanomedicine in terms of drug
delivery with particular reference to which diseases are being targeted generally in Africa. The review will describe the
specific diseases that are being targeted and the progress being made in South Africa, with a view to determining
whether the applications of nanomedicine are being appropriated to address the context-specific challenges in this
country or if they mimic what is being done globally.
Methods: Keywords related to nanomedicine and drug delivery will be combined to build a search strategy for each
of the following databases: PubMed, Cochrane Library (including Cochrane Central Register of Controlled Trials
(CENTRAL), Cochrane Database of Systematic Reviews, Cochrane Methodology Register), Google Scholar, NHS
Health Technology Assessment Database and Web of Science. We will also check reference lists of included studies for
other eligible reports and search unpublished data. To ensure that the search is comprehensive, grey literature will be
searched extensively. Literature to be included will have nanomedicine in drug delivery as the primary application and
report on the specific diseases that are targeted in South Africa. Two authors will independently screen the search
output, select studies and extract data; discrepancies will be resolved by consensus and discussion. When no
consensus is reached, the third author will be consulted
Discussion: The systematic review will inform the government, policy-makers, investors, health professionals, scientists,
and engineers about the applications of nanomedicine in drug delivery. In particular, it will identify the diseases
targeted by the application of nanomedicine for drug delivery and the progress being made in South Africa as the
disease burden of this country differs from that of developed countries where nanomedicine has been widely used for
drug delivery.
Systematic review registration: PROSPERO CRD42017057388
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Background
Nanomedicine is defined in a variety of ways, but an
all-encompassing definition includes the development of
nanoparticles, nanostructured surfaces and nanoanalytical
techniques for molecular diagnostics, treatment, follow-up
and therapy of diseases [1]. Research into the delivery and
targeting of pharmaceutical, therapeutic and diagnostic
agents is at the forefront of nanomedicine [2]. This emer-
ging field brings current advances in chemistry, physics,
biology and materials science to bear on diagnosis and
therapy for a wide range of diseases [3].
The nano-scaled particles used in nanomedicine have
revolutionised drug delivery, allowing therapeutic agents
to be selectively targeted on organ, tissue and cell-specific
levels, while minimising exposure of healthy tissues to
drugs [4]. The use of nanoparticles for drug delivery is
meant to overcome the inherent limitations of
bio-macromolecular therapeutics, which include a short
plasma half-life, poor stability and potential immunogen-
icity [5, 6]. Although conventional drug delivery systems
are effective at releasing drugs in a controlled fashion to
produce a high local concentration, their scope is limited
to targeting tissues rather than individual cells [6].
The ability of nanoparticles to interact with cells and tis-
sues at a molecular level provides them with a distinct
advantage over other polymeric or macromolecular sub-
stances [7]. Nanoparticles are attractive for medical pur-
poses due to their unique features, such as their surface to
mass ratio that is much larger than that of other particles,
their quantum properties and their ability to adsorb and
carry other compounds [8, 9]. Due to the advantage of
their size, nanoparticles have been shown to be robust
drug delivery systems and are useful for encapsulating
drugs and enabling more precise targeting with a con-
trolled release, especially for drugs that have poor solubil-
ity and absorption [10–12]. Some of the applications of
nanoparticles for drug delivery have already reached clin-
ical practice, such as liposomal doxorubicin used to treat
different forms of cancer, or liposomal amphotericin B,
which treats fungal infections often associated with ag-
gressive anti-cancer treatment [13]. Furthermore, one of
the positive outcomes of nanomedicine involves the use of
nanoparticles to deliver drugs through the blood-brain
barrier for targeting brain tumours [14].
New types of intelligent nanoparticles respond to an
externally applied field, be it magnetic, focused heat, or
light, in ways that make them ideal therapeutics or
therapeutic delivery vehicles [15]. The major drive is to
facilitate the identification of precise targets (cells and
receptors) related to specific clinical conditions and to
use the appropriate nanocarriers to achieve the required
responses, while minimising the side effects [16]. This
can make in vivo delivery of drugs that pose serious de-
livery problems, a relatively easy task [17–19]. Drug
release and bio-degradation are important parameters
for developing successful formulations that differ from
conventional therapeutic agents; the latter are distrib-
uted non-specifically in the body where they affect both
diseased and normal cells, thereby limiting the dose
achievable within the diseased cells and also resulting in
sub-optimal treatment due to excessive toxicities [20].
Developed countries have taken a leading role in the
field of nanomedicine as they are investing large amounts
of money into developments in the technology [21]. For
instance, many academic groups in Europe, Japan and the
United States of America are leading nanomedicine re-
search on delivery systems and clinical development of
nanodrugs [22]. In Africa, nanomedicine is an emerging
field, compared to the rest of the world, and the limiting
factor for research is the cost of the required equipment
[23]. South Africa, which is a leading country in terms of
health care services and biomedical research in Africa, is
one of the countries engaged in nanomedicine research
and product development on the continent [24], hence
the focus of this study. The country produces the highest
scientific output per capita on the continent [25]. The pur-
pose of the systematic review is to identify the diseases for
which nanomedicine is used for drug delivery in South Af-
rica and describe the progress made on the disease areas.
This is motivated by the fact that the applications of nano-
medicine tend to differ across countries or regions de-
pending on the disease burden. A study on South Africa
will begin to reveal the focus areas of nanomedicine for
drug delivery in developing countries.
Methods and systematic review design
Study design and scope
We will conduct a systematic review of studies pertaining
to nanomedicine for drug delivery conducted by re-
searchers in South Africa, with a focus on laboratory stud-
ies. This focus is motivated by the fact that nanomedicine
is an emerging and specialised field in South Africa and
much work is limited to fundamental laboratory-based re-
search. All studies on nanomedicine for targeted drug de-
livery in South Africa will be eligible for inclusion.
Primarily, nanomedicine studies include research from
academic institutions, hospitals, research organisations,
and pharmaceutical companies [26]. The study will in-
clude only research with an author affiliation to an institu-
tion in South Africa.
Review questions
The systematic review proposes to address the following
research questions:
a. Which diseases are being targeted for drug delivery
using nanomedicine in South Africa?
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b. What methods of drug delivery using nanomedicine
are being applied for the identified diseases?
c. What progress has been made on the use of
nanomedicine for drug delivery with reference to
the identified disease areas?
Review objectives
In line with the study questions above, the review seeks to
1. Document the diseases which are being targeted for
drug delivery using nanomedicine in South Africa by
a. Identifying the applications of nanomedicine for
drug delivery in South Africa.
b. Synthesising information on the targeted
diseases and the affiliations of the researchers in
South Africa.
c. Critically appraising the disease profiles of studies
forming the evidence base for the applications of
nanomedicine in drug delivery in South Africa.
2. Provide a structured assessment of the progress of
nanomedicine on drug delivery for the identified
diseases in South Africa by
a. Extracting quotes from included studies on the
progress of the nanomedicine for drug delivery
in South Africa.
b. Coding, thematically grouping and iteratively
analysing the data to characterise the progress
in the use of nanomedicine for drug delivery.
Participants/population
The population for this study consists of potential patients
who could be recipients of drug delivery using nanomedi-
cine. As nanomedicine is confined to laboratory studies as
revealed by the preliminary literature search, and the focus
of the proposed review is laboratory studies, included
studies will not include real patients who will have been
treated using the technology in South Africa. However, it
is possible to infer the potential patients since nanomedi-
cine studies target particular diseases and groups of
people. For example, scientists at the Council for Scientific
and Industrial Research in South Africa focus on encapsu-
lating conventional tuberculosis drugs with nanoparticles
to ensure targeted delivery for tuberculosis treatment. We
can deduce from this example that the potential popula-
tion consists of tuberculosis patients. This study, by virtue
of being focused on the different applications of nanome-
dicine for drug delivery, will yield a heterogenous popula-
tion consisting of patients with various disease profiles.
Intervention
Nanomedicine interventions to be included in the study
should aim at drug delivery in South Africa for different
diseases. The following nano-enabled drug delivery
interventions and platforms will be considered for
inclusion: liposome, polymeric drug, drug polymer con-
jugate, protein polymer conjugate, pegylated protein,
nanoparticle, nanocapsule, nano-suspension, nanocrystal,
gold nanoparticle, colloidal gold, silicate nanoparticle,
calcium nanoparticle, biosilic, titanium dioxide nanopar-
ticle, solid lipid nanoparticle, fullerene drug, dendrimer
drug, nanoshell, phototherapy, hypothermal therapy and
magnetic nanoparticle.
Comparison/control
Since nanomedicine is being applied to increase efficacy,
safety, sensitivity and personalisation with the goal of
improved therapy, the control for the study are trad-
itional methods of drug delivery. Initial searches of lit-
erature on the applications of nanomedicine for drug
delivery have shown that by default, use of nanomedi-
cine for drug delivery is compared with existing
practices.
Outcomes
The outcomes of the systematic review will focus on fre-
quency of publication and themes studied across re-
trieved literature. The diseases being targeted using
nanomedicine for drug delivery in South Africa, the pro-
gress in nanomedicine for drug delivery based on the-
matic analysis and the contributing institutions will be
presented, to describe the nanomedicine ecosystem in
South Africa. The relationship between possible drug de-
livery platforms and diseases will be depicted in a map.
Search strategy
We will identify relevant studies within the period starting
in 1 January 2006 to date with language of publication
limited to English. The start date has been selected as 1
January 2006, as this is the time when the South African
nanotechnology strategy and an associated 10-year plan
for nanotechnology were implemented. The databases to
be searched include PubMed (NLM); Scopus; PsycINFO,
EMBASE; Cochrane Library (Wiley) (including Cochrane
Central Register of Controlled Trials (CENTRAL),
Cochrane Database of Systematic Reviews, Cochrane
Methodology Register, NHS Health Technology Assess-
ment Database and Web of Science (Thomson Reuters).
The studies to be included will be selected using prede-
fined search terms adapted for the databases to be used.
The terms comprise both free text word and medical sub-
ject heading (MeSH). We will use a Boolean search string,
which includes keywords, namely, nanomedicine, drug de-
livery and South Africa. PubMed will be used as the pri-
mary database by virtue of being one of the largest
archives of biomedical literature, and it conducts a review
of the scientific quality of journals before indexing [24].
The preliminary search on PubMed is presented in Table 1,
and it will be replicated for the other databases.
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Other sources
Nanomedicine is a specialised topic and as a result, to en-
sure that the search is comprehensive, the grey literature
will be searched extensively. This includes searching rele-
vant conference proceedings, the websites of scientific so-
cieties and pharmaceutical companies, the New York
Academy of Literature and Open Grey. The reference lists
of appropriate studies will be assessed. Full text articles of
the studies extracted from the reference list will be ob-
tained and reviewed for additional information. Unpub-
lished studies will be identified, and the same eligibility
criteria will be applied to select relevant studies.
Study selection
Once the search strategy has been developed and tested,
the first author will retrieve all the relevant articles from
the various databases. All the literature obtained will be
saved in Endnote reference management software for fur-
ther analysis. The titles and abstracts of studies identified
in the literature search will be screened independently by
two authors for eligibility. Prospective studies and studies
retrospectively focusing on the applications of nanomedi-
cine for drug delivery will be included. We acknowledge
that nanomedicine is relatively new in South Africa, and
we will focus on laboratory studies. The final assessment
for inclusion will be made by consensus, based on the full
text of articles. Discrepancies and disagreements will be
resolved by a third author overseeing the review process.
Clear reasons for exclusion will be documented by each
reviewer. Figure 1 outlines the study selection procedures
employed.
Data extraction
A standardised form has been developed and will be
piloted and revised if necessary to extract data from the
eligible studies. Full texts of included abstracts will be
retrieved and data extracted as per the pre-specified
template (Additional file 1). Key information to be ex-
tracted includes:
 Author/s and year of the study
 Type of facility/environment
 Affiliation of author
 Type of participant/study population/demographic
characteristics
 Type of nanomedicine drug delivery intervention
 Type of targeted disease
 Type of study (i.e. study design)
 Type of outcome measured
 Findings/results
Data will be entered into Review Manager (RevMan)
software, Version 5.3. (Copenhagen: The Nordic Cochrane
Centre, the Cochrane Collaboration, 2011). The first and
second authors will verify the data entered, for missing or
incorrect data. When deemed necessary, the authors of
studies will be contacted for missing or incomplete data.
Should there be no response from the authors, the limited
data available will be included and the implications of
missing/incomplete data will be discussed.
Data analysis and synthesis
The extracted data will be presented in an evidence table
organised by targeted diseases, methods used for drug
delivery, institutions and/or stakeholders involved, and
milestones achieved in nanomedicine. We will review
the use and progress of nanomedicine for drug delivery
in South Africa by developing descriptive themes to an-
swer each research question and synthesise extracted
data through a narrative synthesis [27]. The heterogen-
eity of the studies reviewed will be explored through
narrative synthesis. As per Popay et al. [28], we will syn-
thesise insights derived from the reviewed literature in
order to provide a nuanced description of how nanome-
dicine is being applied for drug delivery in South Africa,
including an account of the methods of drug delivery
and the progress made. Two reviewers will code the ex-
tracted data independently and conduct a thematic ana-
lysis to determine the patterns that are associated with
the research questions. The findings will be mapped to
create a holistic picture of the landscape of nanomedi-
cine for drug delivery in South Africa. Studies with the
same or related outcomes, study setting (e.g. university,
science council, non-governmental organisation), target
disease (e.g. HIV, TB, cancer), drug delivery (e.g. liposome,
Table 1 Search strings for extracted literature
Population
#1 MeSH terms: Drug Delivery Systems
#2 All Fields: drug delivery OR targeted drug OR
drug targeting
#3 #1 OR #2
Intervention
#4 MeSH terms: Nanotechnology OR Nanostructures
#5 All fields: Nanomedicine OR Nanotechnology
#6 #4 OR #5
Outcome
#7 MeSH terms: South Africa
#8 Free text: South Africa OR South African
#9 #7 OR #8
#10 #3 AND #6 AND #9 January 2006 to April 2018
#11 Filter #10 by specifying
the time period
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nanoparticle, drug polymer conjugate) or type of study
(e.g. laboratory study) will be pooled to facilitate analysis
of the data. Figure 2 shows an example of data synthesis;
it portrays the application of nanoparticles, the drug deliv-
ery platform used, and the type of disease [29–31]. Figure 2
shows that cancer is targeted by gold and silver nanoparti-
cles [30]. Breast and lung cancer are the types of cancers
that are targeted. Polymeric nanoparticles are drug deli-
very platform that is also used in HIV [31], whereas nano-
spheres target asthma, which is a respiratory disease [29].
The preliminary sketch depicted in Fig. 2 on nanomedi-
cine and diseases being targeted in South Africa will be ex-
panded to include the institutions involved and how they
are connected. The progress in the use of nanomedicine
on the targeted diseases will be analysed in relation to con-
ventional treatment.
Discussion
The surge of applications of nanotechnology in developed
countries has raised questions, with some scholars arguing
that inequitable distribution of the benefits and profits will
occur and accumulate in the north [32]. Nanomedicine, a
recent offshoot of nanotechnology, is assumed to follow
the same trajectory. Since 2005, South Africa has invested
in research on nanomedicine focusing on pro-poor initia-
tives which prioritise diseases such as HIV/AIDS, malaria
and tuberculosis. Considering the human, financial, and
physical resources that the country has invested in
Fig. 1 Selection criteria applied to abstracts retrieved via literature search
Fig. 2 Example of nanomedicine applications depicting the platforms for drug delivery and diseases being targeted in South Africa [29–31]
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nanomedicine, it is time to reflect on how the research is
progressing. The proposed systematic review will inform
further research and innovation in terms of research activ-
ities in South Africa in the field of nanomedicine.
We acknowledge the limitation that our review is re-
stricted to laboratory studies as clinical trial results are
not yet available. Since there are few laboratories in South
Africa that are designed to handle research on materials at
nanoscale, we acknowledge that we may not be able to
conduct a meta-analysis due to limited research activity.
The initial scoping exercises which we conducted revealed
that there are few, but dominant, research groups that en-
gage in nanomedicine and it is more likely that the review
will be limited to a few South African institutions and re-
searchers. In addition, the reliance on published data may
predispose the review to publication bias.
Despite the limitations mentioned above, the proposed
systematic review is of value both theoretically and practic-
ally. The study aims to provide an up to date account of
the application of nanomedicine for drug delivery in South
Africa. We seek to identify the diseases targeted for drug
delivery using nanomedicine and synthesise information
not only on the methods of intervention but also the pro-
gress made so far. The review will be essential to health
professionals, policy-makers, funding organisations and the
public at large in establishing the extent to which South
Africa, a leading country in providing health care services
and conducting biomedical research in sub-Saharan Africa,
is exploiting the new opportunities provided by nanomedi-
cine for the benefit of its health system.
Report
This systematic protocol has been registered with
PROSPERO, the international prospective register of system-
atic reviews. The registration number is CRD42017057388.
The authors acknowledge that it adheres to the PRISMA-P
2015 checklist as a condition for submission of systematic re-
view protocols (see Additional file 2). The review will follow
the recommendations of the Cochrane handbook for system-
atic reviews of interventions for the design and analysis plan
development and the preferred reporting items for system-
atic reviews and meta-analyses (PRISMA) will be followed in
presenting the results.
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Additional file 1: Data extraction form. (DOC 135 kb)
Additional file 2: PRISMA-P 2015 checklist. (DOCX 31 kb)
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